These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27014702)

  • 1. Engineering and Evolution of Molecular Chaperones and Protein Disaggregases with Enhanced Activity.
    Mack KL; Shorter J
    Front Mol Biosci; 2016; 3():8. PubMed ID: 27014702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering enhanced protein disaggregases for neurodegenerative disease.
    Jackrel ME; Shorter J
    Prion; 2015; 9(2):90-109. PubMed ID: 25738979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering therapeutic protein disaggregases.
    Shorter J
    Mol Biol Cell; 2016 May; 27(10):1556-60. PubMed ID: 27255695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Insights into Hsp104 Potentiation.
    Torrente MP; Chuang E; Noll MM; Jackrel ME; Go MS; Shorter J
    J Biol Chem; 2016 Mar; 291(10):5101-15. PubMed ID: 26747608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and α-Synuclein Proteotoxicity.
    Tariq A; Lin J; Jackrel ME; Hesketh CD; Carman PJ; Mack KL; Weitzman R; Gambogi C; Hernandez Murillo OA; Sweeny EA; Gurpinar E; Yokom AL; Gates SN; Yee K; Sudesh S; Stillman J; Rizo AN; Southworth DR; Shorter J
    Cell Rep; 2019 Aug; 28(8):2080-2095.e6. PubMed ID: 31433984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing deleterious protein aggregation with re-engineered protein disaggregases.
    Jackrel ME; Shorter J
    Cell Cycle; 2014; 13(9):1379-83. PubMed ID: 24694655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer protein disaggregases to counter neurodegenerative disease.
    Shorter J
    Curr Opin Genet Dev; 2017 Jun; 44():1-8. PubMed ID: 28208059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.
    Jackrel ME; DeSantis ME; Martinez BA; Castellano LM; Stewart RM; Caldwell KA; Caldwell GA; Shorter J
    Cell; 2014 Jan; 156(1-2):170-82. PubMed ID: 24439375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolating potentiated Hsp104 variants using yeast proteinopathy models.
    Jackrel ME; Tariq A; Yee K; Weitzman R; Shorter J
    J Vis Exp; 2014 Nov; (93):e52089. PubMed ID: 25407485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate Discrimination by ClpB and Hsp104.
    Johnston DM; Miot M; Hoskins JR; Wickner S; Doyle SM
    Front Mol Biosci; 2017; 4():36. PubMed ID: 28611991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.
    Jackrel ME; Shorter J
    Dis Model Mech; 2014 Oct; 7(10):1175-84. PubMed ID: 25062688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drivers of Hsp104 potentiation revealed by scanning mutagenesis of the middle domain.
    Ryan JJ; Bao A; Bell B; Ling C; Jackrel ME
    Protein Sci; 2021 Aug; 30(8):1667-1685. PubMed ID: 34010483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.
    Tariq A; Lin J; Noll MM; Torrente MP; Mack KL; Murillo OH; Jackrel ME; Shorter J
    FEMS Yeast Res; 2018 Aug; 18(5):. PubMed ID: 29788207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate Mutations Confer Therapeutic Gain of Hsp104 Function.
    Jackrel ME; Yee K; Tariq A; Chen AI; Shorter J
    ACS Chem Biol; 2015 Dec; 10(12):2672-9. PubMed ID: 26441009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skd3 (human ClpB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations.
    Cupo RR; Shorter J
    Elife; 2020 Jun; 9():. PubMed ID: 32573439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
    Sharma SK; Priya S
    Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteostasis and the Regulation of Intra- and Extracellular Protein Aggregation by ATP-Independent Molecular Chaperones: Lens α-Crystallins and Milk Caseins.
    Carver JA; Ecroyd H; Truscott RJW; Thorn DC; Holt C
    Acc Chem Res; 2018 Mar; 51(3):745-752. PubMed ID: 29442498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural mechanisms of chaperone mediated protein disaggregation.
    Sousa R
    Front Mol Biosci; 2014; 1():12. PubMed ID: 25988153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of Calcarisporiella thermophila Hsp104 Disaggregase that Antagonizes Diverse Proteotoxic Misfolding Events.
    Michalska K; Zhang K; March ZM; Hatzos-Skintges C; Pintilie G; Bigelow L; Castellano LM; Miles LJ; Jackrel ME; Chuang E; Jedrzejczak R; Shorter J; Chiu W; Joachimiak A
    Structure; 2019 Mar; 27(3):449-463.e7. PubMed ID: 30595457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.